Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. reports developments across a diversified biopharmaceutical business built around a core royalty portfolio, Innoviva Specialty Therapeutics, and strategic healthcare investments. Recurring updates cover royalty revenue from GSK-related respiratory products, IST commercial performance in critical care and infectious disease medicines, and capital allocation actions such as share repurchases.
Company news also includes regulatory and clinical developments for IST antibiotics, including NUZOLVENCE (zoliflodacin) for uncomplicated urogenital gonorrhea, ZEVTERA updates, medical-conference presentations, and changes in the value of strategic healthcare assets such as Armata Pharmaceuticals investments.
Innoviva (NASDAQ: INVA) reported Q1 2026 results with $98.0M total revenue, driven by a resilient royalty portfolio and IST commercial growth. Net product sales were $41.4M (37% YoY), royalty revenue from GSK was $58.6M, and net income was $186.6M ($2.52 basic EPS) including a $191.2M favorable fair-value gain. Cash totaled $603.1M. IST received FDA approval for NUZOLVENCE in Dec 2025 and expects patient availability in H2 2026. The company repurchased 971,066 shares for $20.4M in Q1 under a $125M program.
Innoviva (NASDAQ: INVA) reported strong 2025 results with total revenue of $411.3M (up 15% YoY) and net income of $271.2M (basic EPS $4.02). IST U.S. net product sales grew 47% YoY to $119.2M. Royalty revenue was $250.3M for the year.
Key corporate developments include FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea, a $125M share repurchase program, a strategic asset portfolio valued at $614.0M, and $550.9M in cash and equivalents.
Innoviva (NASDAQ: INVA) said management will take part in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 10:00 a.m. ET. The conference is virtual and the session will be webcast live.
According to the company, the live webcast is available under Events & Presentations in the Investor Relations section at https://investor.inva.com/presentations-events, and an archived replay will be posted after the event.
Innoviva (NASDAQ: INVA) announced U.S. FDA approval of NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral suspension for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents 12+ years weighing ≥35 kg.
Approval was supported by the largest Phase 3 trial ever for a new gonorrhea treatment across five countries and showed non-inferiority to current injectable therapy, including against drug-resistant strains. The company plans commercialization in H2 2026, either with a partner or independently.
Innoviva Specialty Therapeutics (NASDAQ: INVA) announced publication in The Lancet of positive Phase 3 data showing single‑dose oral zoliflodacin was non‑inferior to ceftriaxone plus azithromycin for uncomplicated urogenital gonorrhea (difference 5.31%, 95% CI 1.38%–8.65%).
The trial reported comparable extragenital microbiological cure and similar safety with no serious adverse events. Zoliflodacin has QIDP designation and the FDA accepted the NDA in June 2025 with a PDUFA target action date of December 15, 2025.
Innoviva (NASDAQ: INVA) said management will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025 at 4:30 p.m. Eastern Time.
A live webcast will be available under “Events & Presentations” in the company’s Investor Relations site at https://investor.inva.com/presentations-events, and an archived replay will be posted after the event.
Innoviva (NASDAQ: INVA) reported third-quarter 2025 results and corporate developments on November 5, 2025. Total revenue was $107.8 million, up 20% year‑over‑year; gross royalty revenue from GSK was $63.4 million; net product sales were $47.3 million (U.S. $29.9M, ex‑U.S. $17.4M) with U.S. sales up 52% YoY. Net income was $89.9 million ($1.30 basic EPS). Cash and equivalents totaled $476.5 million. Key operational items: U.S. commercial launch of ZEVTERA, zoliflodacin PDUFA target date of Dec 15, 2025, and favorable fair‑value gains of $62.3 million on equity investments. The Board authorized a $125.0 million share repurchase program.
Antheia (NASDAQ:INVA) appointed Eric d'Esparbes as Chief Financial Officer effective Oct. 21, 2025. d'Esparbes will lead financial strategy and operations as Antheia advances commercialization and seeks to unlock U.S. manufacturing capabilities.
The hire follows a $56 million Series C fundraise in June 2025 and the company’s first commercial product launch in 2024. d'Esparbes brings three decades of senior finance experience, including prior CFO roles and leading an IPO in 2020.
Innoviva Specialty Therapeutics (NASDAQ: INVA) will present new analyses from the pivotal Phase 3 trial of zoliflodacin, a single‑dose oral antibiotic for uncomplicated gonorrhea, at IDWeek 2025 in Atlanta, October 19–22, 2025.
Three presentations include two posters (P-1206, P-1207 on Oct 21) and an oral presentation (Oct 22) reporting high microbiological cure rates across urogenital, rectal, and pharyngeal sites for isolates with zoliflodacin MIC ≤0.25 µg/mL. Urogenital cure rates were 96.6% (346/358; 95% CI 94.2–98.3) for ciprofloxacin‑resistant strains and 97.4% (113/116; 95% CI 92.6–99.5) for ciprofloxacin‑susceptible strains. Posters show comparable zoliflodacin MICs across demographic groups and stable potency in U.S. 2022 isolates versus 2020–2021.
Innoviva Specialty Therapeutics (NASDAQ: INVA) will present six scientific items from its infectious diseases and critical care portfolio at IDWeek 2025 in Atlanta, October 19–22, 2025. Presentations include clinical data, PK‑PD analyses, and microbiologic surveillance on zoliflodacin, ceftobiprole, sulbactam‑durlobactam, and eravacycline.
Highlights: an oral subset analysis from the Phase 3 zoliflodacin trial (Oct 22) and an oral PK‑PD target attainment analysis for ceftobiprole in Staphylococcus aureus bacteremia (Oct 22). Multiple poster presentations on pediatric pharmacokinetics and U.S. zoliflodacin activity are scheduled Oct 20–22. Visit booth #1231 for more information.